February 10, 2025 03:15 PM EST
Deals
Pharma

Eli Lil­ly inks $630M deal for Phase 1 MASH can­di­date

Nicole DeFeudis

Editor

Eli Lil­ly is bet­ting up to $630 mil­lion on an ex­per­i­men­tal MASH treat­ment from a South Ko­re­an biotech.

The phar­ma gi­ant

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Judge halts some NIH cuts af­ter 22 states sue

Hims’ Su­per Bowl ad has drawn crit­i­cism from law­mak­ers — and now No­vo Nordisk

Mer­ck KGaA con­firms in­ter­est in ac­quir­ing can­cer biotech Spring­Works

Decade af­ter $8B deal, Roche of­floads In­ter­Mune to mys­te­ri­ous spe­cial­ty phar­ma

States sue Trump ad­min­is­tra­tion over bil­lions in NIH in­di­rect cost cuts

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times